2018/19 Vaccination and immunisations


Immunisation is one of the most successful and cost-effective public health interventions and a cornerstone of public health. High immunisation rates are key to preventing the spread of infectious disease, complications and possible early death among individuals. Immunisation also helps protect the population’s health through both individual and herd immunity.

Following recommendations from the Joint Committee on Vaccinations and Immunisations (JCVI), a number of programmes are commissioned for delivery by general practice. This includes those which are legally directed by the Secretary of State for Health to establish or offer, and those NHS England has prescribed. Some enhanced services (ES) delivered by GMS practices have payments directed in the statement of financial entitlements (SFE). The full set of enhanced services can be found on the NHS England enhanced services webpage.

From 1 April 2018, the item of service (IoS) fee for the following vaccinations was increased from £9.80 to £10.06 per dose in line with the consumer price inflation (CPI) index:

  • Hepatitis B at-risk (new-born babies)
  • HPV completing dose
  • Meningococcal B
  • Meningococcal ACWY freshers
  • Meningococcal completing dose
  • MMR
  • Rotavirus
  • Singles routine
  • Shingles catch-up

The IoS fee for the following programmes is unchanged at £9.80 per dose:

  • Childhood seasonal influenza
  • Pertussis
  • Seasonal influenza and pneumococcal polysaccharide

The payment for pneumococcal PCV will remain at £15.02.

A number of changes have been agreed to the vaccination and immunisation programmes.

  • Hepatitis B (newborn babies) – programme name changed to hepatitis B at-risk (newborn babies). Vaccine changes and number of recommended doses reduced to three, therefore the payment of the second dose has now been uncoupled from the third dose. This was an in-year change effective 30 October 2017, included for completeness.
  • MenACWY 18 years on 31 August – programme removed.
  • Meningococcal completing dose – cohort extended to include eligible school leavers previously covered by the 18 years programme. The eligibility is now 1 April 2012.
  • Meningococcal B – programme moved in to the SFE, but is not included in the targeted programme. There are no changes to eligibility of payment requirements.
  • Pneumococcal PCV three-month dose – there is a consultation underway relating to the removal of one dose of PCV from the childhood programme. In the event this change is agreed, funding for the remaining dose will remain at £15.02. 

The following programmes continue unchanged:

  • childhood seasonal influenza
  • hepatitis B at-risk (babies)
  • human papilloma virus (HPV) completing dose (adolescent girls)
  • measles mumps and rubella (aged 16 and over)
  • MenACWY freshers
  • pertussis
  • pneumococcal polysaccharide (PPV)
  • rotavirus
  • seasonal influenza
  • shingles (routine)
  • shingles (catch-up)

Download a summary of the new and amended programmes.

The requirements for the following vaccination programmes are available in the service specifications which are available to download from the NHS England webpage.

Details of these programmes are available in the vaccination and immunisation programmes 2018/19 guidance and audit requirements document.

Download the technical requirements document for the 2018/19 contract changes.

A set of FAQs were developed to support commissioners in delivery of the 2017/18 GMS contract, they can be found on our FAQs page. This page will be updated to include 2018/19 FAQs mid-late 2018.

Latest Tweets

Latest Blog Post

Stay curious and open - key messages from ODN Europe

17 / 7 / 2019 12.48pm

OD practitioner Ruth Ball shares her experiences from the ODN Europe conference.

Why Register?

Great reasons to register with NHS Employers

  • A personalised website
    Manage your profile and select topics of interest to you
  • Access your dashboard
    Bookmark useful content to help you quickly find what you're looking for
  • Get involved
    Contribute to our Talking Points discussions, comment on and rate our webpages
  • Keep up to date
    Receive the latest newsletters and media summaries

Log In